关于欧盟/欧洲经济区在2025年实现可持续发展目标3.3关于艾滋病、结核病、病毒性肝炎和性传播感染目标进展的概述

Data from 2023−2024 ECDCSURVEILLANCE & MONITORING Overview of progress towards theSustainable Development Goal 3.3 targetson HIV, tuberculosis, viral hepatitis andsexually transmitted infections in theEU/EEA, 2025 Data from 2023−2024 This report of the European Centre for Disease Prevention and Control was coordinated by Charlotte Deogan with support fromTeymur Noori, Veronica Cristea, Senia Rosales-Klintz, Erika Duffell and Lina Nerlander. The draft version of the report was produced by the Centre of Excellence for Health, Immunity and Infections (CHIP) inCopenhagen, Denmark, under Specific contract No 11 ECD.18216. It was written by Annemarie Rinder Stengaard, with input fromMarie-Louise Jakobsen, Oleksandr Korotych, Sarah North, Anne Raahauge and Dorthe Raben. This report is one in a series of thematic reports on progress towards Sustainable Development Goal 3.3 related to HIV, viralhepatitis, sexually transmitted infections and tuberculosis based on information submitted by reporting countries between 2023and 2025. Other reports in the series can be found on ECDC’s website:Sustainable Development Goals. AcknowledgementsECDC would like to acknowledge the support and guidance provided by members of the ECDC monitoring advisory groups for HIV(Dublin Declaration monitoring), viral hepatitis, sexually transmitted infections and tuberculosis. Suggested citation: European Centre for Disease Prevention and Control. Overview of progress towards the SustainableDevelopment Goal 3.3 targets on HIV, tuberculosis, viral hepatitis and sexually transmitted infections in the EU/EEA, 2025 – Datafrom 2023−2024. Stockholm: ECDC; 2026. Stockholm, May 2026 Contents Abbreviations ............................................................................................................................................... ivExecutive summary ........................................................................................................................................1Incidence .................................................................................................................................................1Prevention ...............................................................................................................................................1Testing ....................................................................................................................................................1Treatment................................................................................................................................................2Mortality ..................................................................................................................................................2Conclusions..............................................................................................................................................21 Introduction ...............................................................................................................................................32 Methods .....................................................................................................................................................43 Progress towards the SDG 3.3 targets in the EU/EEA......................................................................................53.1 Incidence (new infections) ...................................................................................................................53.2 Prevention targets...............................................................................................................................73.3 Testing targets....................................................................................................................................93.4 Treatment targets .............................................................................................................................11HIV ...................................................................................................................................................12Tuberculosis.......................................................................................................................................14Hepatitis ............................................................................................................................................14Sexually transmitted infections.............................................................................................................153.5 Mortality targets................................................................................................................................154 Limitations................................................................................................................................................175 Conclusions .........................................................................................